Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh ...

MSD is also betting on Hansoh’s candidate working in more indications than just obesity. The drugmaker already has a ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...

Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs ...

Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Amidst an evolving field of competitors, the big pharma is ...

Merck just licensed a weight-loss drug candidate. There's reason to believe that the candidate could have a big edge. But, success is not guaranteed, and the program will take years to develop.

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes an upfront $112 million licensing rights payment for ...

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, is now a $258 billion (by market cap) healthcare behemoth. The US is ...

Merck has announced plans to invest over EUR70 million(US$72.53 million) to construct a new advanced materials development center (AMDC) at its Shizuoka site in Japan. This latest investment ...